POP-D 0.075 mg (Tablet)

Title

• POP-D Contraceptive Pill

Categories

• Oral Contraceptive preparations

Description

• Contains progestogen-only-pill (POP), does not contain estrogen hormone, high contraceptive efficacy, suitable for women who do not tolerate estrogens and women who are breastfeeding, may cause irregular vaginal bleeding

Indications

• Used to provide contraceptive efficacy in women who want to prevent pregnancy, alternative for women who have weak tolerance levels for estrogen hormones, or who are lactating or breastfeeding

Dosage & Administration

• Take one tablet at the same time each day, taken continuously without a break, should be taken within 3 hours of the same time each day, comes in a strip with 28 tablets, tablets should be taken within 3 hours of the same time each day

Drug Interactions

• Enzyme-inducing drugs may result in increased clearance and lead to breakthrough bleeding and contraceptive failure, may be seen with hydantoins, barbiturates, primidone, carbamazepine, rifampicin, oxcarbazepine, rifabutin, felbamate, ritonavir, griseofulvin and products containing St John's Wort, reduced absorption of etonogestrel may be seen with medical charcoal

Contraindications

• Known or suspected pregnancy, active venous thromboembolic disorder, presence or history of severe hepatic disease, progestogen dependent tumors, undiagnosed vaginal bleeding, hypersensitivity to ingredients

Side Effects

• Common: irregular bleeding, amenorrhoea, headache, weight gain, breast pain, nausea, acne, mood changes, decreased libido, Less common: Vaginitis, dysmenorrhoea, ovarian cysts, vomiting, alopecia, fatigue, difficulty wearing contact lenses, Rare: Rash, urticaria, erythema nodosum

Pregnancy & Lactation

• Not recommended for use during pregnancy, does not affect the production or quality of breast milk, small amounts of the metabolite etonogestrel are excreted with the milk, long term follow-up data are not available, however 7 month data do not indicate a risk to the nursing infant

Precautions & Warnings

• Associated with an increased incidence of venous thromboembolism, unclear if POP-D used alone carries the same risk, discontinue in the event of a thrombosis, consider stopping prior to long term immobilization, benefit/risk assessment should be made in women with liver cancer, caution patients with a history of thromboembolic disorders, carefully monitor patients with diabetes, effects on bone density are unknown

Overdose Effects

• No serious deleterious effects reported from an overdose, may include nausea, vomiting, and slight vaginal bleeding in young girls, treatment should be symptomatic

Storage Conditions

• Store at room temperature (below 30°C), do not use it after the expiry date stated on the package

Related Brands

• Bredicon 0.075 mg (Tablet) - renata-limited